EP1244683A4 - 21 human secreted proteins - Google Patents
21 human secreted proteinsInfo
- Publication number
- EP1244683A4 EP1244683A4 EP00977043A EP00977043A EP1244683A4 EP 1244683 A4 EP1244683 A4 EP 1244683A4 EP 00977043 A EP00977043 A EP 00977043A EP 00977043 A EP00977043 A EP 00977043A EP 1244683 A4 EP1244683 A4 EP 1244683A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- secreted proteins
- human secreted
- human
- proteins
- secreted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16483599P | 1999-11-12 | 1999-11-12 | |
US164835P | 1999-11-12 | ||
US22114200P | 2000-07-27 | 2000-07-27 | |
US221142P | 2000-07-27 | ||
PCT/US2000/030654 WO2001034629A1 (en) | 1999-11-12 | 2000-11-08 | 21 human secreted proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1244683A1 EP1244683A1 (en) | 2002-10-02 |
EP1244683A4 true EP1244683A4 (en) | 2005-01-12 |
Family
ID=26860899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00977043A Withdrawn EP1244683A4 (en) | 1999-11-12 | 2000-11-08 | 21 human secreted proteins |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1244683A4 (en) |
JP (3) | JP5583308B2 (en) |
AU (1) | AU1473501A (en) |
CA (1) | CA2387959A1 (en) |
WO (1) | WO2001034629A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7202342B1 (en) | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7264926B2 (en) | 2000-04-18 | 2007-09-04 | Millennium Pharmaceuticals, Inc. | Nucleoside Phosphatase |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP1292619B1 (en) | 2000-06-06 | 2008-02-06 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
EP1892251A3 (en) * | 2000-06-06 | 2008-12-31 | Brystol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
NZ522844A (en) * | 2000-06-28 | 2005-02-25 | Brigham & Womens Hospital | PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation |
EP1305428A2 (en) * | 2000-07-14 | 2003-05-02 | Millennium Pharmaceuticals, Inc. | 62088, a human nucleoside phosphatase family member and uses thereof |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
EP1328624B1 (en) * | 2000-09-20 | 2011-11-09 | Amgen Inc. | B7-like molecules and uses thereof |
AU2006202524B2 (en) * | 2000-09-20 | 2009-12-03 | Amgen, Inc. | B7-Like Molecules and Uses Thereof |
US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP1352961B1 (en) * | 2000-12-22 | 2018-06-27 | Toshihiro Nakajima | Synovial cell protein |
DE10215601B4 (en) | 2002-04-10 | 2005-08-04 | Henkel Kgaa | Water-soluble container and process for its preparation and use |
WO2005016367A1 (en) * | 2003-08-13 | 2005-02-24 | Locomogene, Inc. | Therapeutic preparation for hematopoietic disease |
PT1810026T (en) | 2004-10-06 | 2018-06-11 | Mayo Found Medical Education & Res | B7-h1 and pd-1 in treatment of renal cell carcinoma |
PL2397156T3 (en) | 2005-06-08 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway |
CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2013073968A2 (en) * | 2011-09-12 | 2013-05-23 | Industrial Research Limited | Agents for modulation of cell signalling |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2015050663A1 (en) | 2013-10-01 | 2015-04-09 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of bim |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055375A1 (en) * | 1999-03-17 | 2000-09-21 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
EP1074617A2 (en) * | 1999-07-29 | 2001-02-07 | Helix Research Institute | Primers for synthesising full-length cDNA and their use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997004097A2 (en) * | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
US5807703A (en) * | 1996-06-17 | 1998-09-15 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5831056A (en) * | 1996-06-07 | 1998-11-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
AU8504098A (en) | 1997-07-22 | 1999-02-16 | University Of Maryland | Methods of modifying the butyrophilin protein to eliminate an autoimmune response and products associated therewith |
JP2002191363A (en) * | 1999-07-29 | 2002-07-09 | Herikkusu Kenkyusho:Kk | PRIMER FOR WHOLE LENGTH cDNA SYNTHESIS AND ITS USE |
-
2000
- 2000-11-08 WO PCT/US2000/030654 patent/WO2001034629A1/en active Application Filing
- 2000-11-08 CA CA002387959A patent/CA2387959A1/en not_active Abandoned
- 2000-11-08 JP JP2001537340A patent/JP5583308B2/en not_active Expired - Fee Related
- 2000-11-08 EP EP00977043A patent/EP1244683A4/en not_active Withdrawn
- 2000-11-08 AU AU14735/01A patent/AU1473501A/en not_active Abandoned
-
2010
- 2010-11-25 JP JP2010263015A patent/JP2011087587A/en active Pending
-
2013
- 2013-07-05 JP JP2013141728A patent/JP2013233148A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000055375A1 (en) * | 1999-03-17 | 2000-09-21 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
EP1074617A2 (en) * | 1999-07-29 | 2001-02-07 | Helix Research Institute | Primers for synthesising full-length cDNA and their use |
Non-Patent Citations (4)
Title |
---|
DATABASE EMBL EBI; 12 March 1997 (1997-03-12), LIEW C C: "cDNA's from fetal heart", XP002293280, Database accession no. AA247117 * |
DATABASE EMBL EBI; 17 December 2003 (2003-12-17), XP002293282, Database accession no. AX877717 * |
DATABASE EMBL EBI; 28 August 1996 (1996-08-28), HILLIER ET AL: "The WashU-Merck EST Project", XP002293279, Database accession no. AA036918 * |
See also references of WO0134629A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003513655A (en) | 2003-04-15 |
CA2387959A1 (en) | 2001-05-17 |
JP2013233148A (en) | 2013-11-21 |
JP5583308B2 (en) | 2014-09-03 |
JP2011087587A (en) | 2011-05-06 |
EP1244683A1 (en) | 2002-10-02 |
AU1473501A (en) | 2001-06-06 |
WO2001034629A1 (en) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1218408A4 (en) | 32 human secreted proteins | |
EP1212343A4 (en) | 52 human secreted proteins | |
EP1181390A4 (en) | 27 human secreted proteins | |
EP1244683A4 (en) | 21 human secreted proteins | |
EP1224285A4 (en) | 27 human secreted proteins | |
EP1212342A4 (en) | 18 human secreted proteins | |
EP1226231A4 (en) | 19 human secreted proteins | |
EP1175438A4 (en) | 62 human secreted proteins | |
EP1192176A4 (en) | 49 human secreted proteins | |
EP1192278A4 (en) | 48 human secreted proteins | |
EP1175439A4 (en) | 49 human secreted proteins | |
EP1165827A4 (en) | 45 human secreted proteins | |
EP1159284A4 (en) | 33 human secreted proteins | |
EP1189917A4 (en) | 48 human secreted proteins | |
EP1185543A4 (en) | 50 human secreted proteins | |
EP1224201A4 (en) | 32 human secreted proteins | |
EP1173477A4 (en) | 49 human secreted proteins | |
EP1206573A4 (en) | 26 human secreted proteins | |
EP1203005A4 (en) | 25 human secreted proteins | |
EP1144614A4 (en) | 33 human secreted proteins | |
EP1169332A4 (en) | 49 human secreted proteins | |
EP1171460A4 (en) | 48 human secreted proteins | |
EP1165602A4 (en) | 49 human secreted proteins | |
EP1165828A4 (en) | 50 human secreted proteins | |
EP1228082A4 (en) | 29 human secreted proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020522 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 1/21 B Ipc: 7C 12N 15/63 B Ipc: 7C 07K 14/47 B Ipc: 7C 12Q 1/68 B Ipc: 7C 12N 15/12 A Ipc: 7C 07K 16/18 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041129 |
|
17Q | First examination report despatched |
Effective date: 20050513 |
|
17Q | First examination report despatched |
Effective date: 20050513 |
|
17Q | First examination report despatched |
Effective date: 20050513 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100531 |